Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

Recent News
Aug 14, 2024
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b...

Aug 7, 2024
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update...

Jul 1, 2024
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK, July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of...

View All

Events
Brainstorm Cell Therapeutics Second Quarter 2024 Earnings Call
Wednesday, August 14, 2024
8:30am - 9:30am EDT

The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.

Replay Numbers
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 51009

View All

Email Alerts
Email Alerts
Investor Contact
Investor Contact
Investor FAQs
Investor FAQs
RSS Feeds
RSS Feeds
Investors